Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High Non-small Cell Lung Cancer

• Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.
• >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy.
• Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations.
• GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting